

the committee. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 10:30 a.m. on October 25, 2018. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 1, 2018. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 2, 2018.

Persons attending FDA's advisory committee meetings are advised that FDA is not responsible for providing access to electrical outlets.

For press inquiries, please contact the Office of Media Affairs at fdoma@fda.hhs.gov or 301-796-4540.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact LaToya Bonner (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 13, 2018.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2018-20233 Filed 9-17-18; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC)/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT) has scheduled a public meeting. Information about the CHACHSPT can be found here: <https://www.cdc.gov/maso/facm/facmchachspt.html>. An agenda may be requested by emailing CHACAdvisoryComm@hrsa.gov.

DATES: November 7, 2018, 8:30 a.m.–5:00 p.m. ET and November 8, 2018, 8:30 a.m.–3:30 p.m. ET.

ADDRESSES: This meeting will be held in-person and by webinar and teleconference. The address for the meeting is DoubleTree by Hilton, Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.

- *Adobe Connect URL link:* https://hrsa.connectsolutions.com/chac_meeting/.

- *Conference call-in number:* 888-324-9617, Passcode 9245865.

FOR FURTHER INFORMATION CONTACT:

Theresa Jumento, Chief, Policy Development Branch, HRSA, HIV/AIDS Bureau (HAB), Division of Policy and Data, 5600 Fishers Lane, Room 9N156, or by email at CHACAdvisoryComm@hrsa.gov.

SUPPLEMENTARY INFORMATION: The CHACHSPT was established under Section 222 of the Public Health Service (PHS) Act, [42 U.S.C. Section 217a], as amended.

The purpose of the CHACHSPT is to advise the Secretary of HHS, the Director of the CDC, and the Administrator of HRSA on the objectives, strategies, policies, and priorities for HIV, viral hepatitis, and other STD prevention and treatment efforts. This includes, but is not limited to, surveillance of HIV infection, viral hepatitis, and other STDs; responses to related emerging health needs; and epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS, viral hepatitis, and other STDs. The CHACHSPT also provides advice regarding policy issues related to

HIV/viral hepatitis/STD professional education, patient healthcare delivery, research and training, and prevention services.

During the November 7–8, 2018, meeting, the CHACHSPT will discuss the following topics:

- CHACHSPT workgroup reports and findings;
- updates from CDC, HRSA, and HRSA HAB;
- strategies for serving women, infants, children, and youth;
- agencies' responses to the opioid crisis; and
- telemedicine initiatives.

Agenda items are subject to change as priorities dictate. Refer to the CHACHSPT website for any updated information concerning the meeting.

Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting. Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to CHACHSPT should be sent by email to CHACAdvisoryComm@hrsa.gov or by mail to Theresa Jumento at the address above at least 3 business days prior to the meeting.

Individuals who plan to attend and need special assistance or another reasonable accommodation should notify Theresa Jumento at the address listed above at least 10 business days prior to the meeting.

Amy P. McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2018-20269 Filed 9-17-18; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Advisory Council on Migrant Health

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Meeting notice.

SUMMARY: The Secretary's National Advisory Council on Migrant Health (NACMH) has scheduled a public meeting. Information about NACMH and the agenda for this meeting can be found on the NACMH website at: <https://bphc.hrsa.gov/qualityimprovement/strategicpartnerships/nacmh/index.html>.

DATES: November 14, 2018, 8:30 a.m.–5:00 p.m. ET and November 15, 2018, 9:00 a.m.–5:00 p.m. ET.

ADDRESSES: This meeting will be held in person only at the Bethesda Marriott Suites. The address for the meeting is 6711 Democracy Boulevard, Bethesda, Maryland 20817. Phone: 301–897–5600.

FOR FURTHER INFORMATION CONTACT: Esther Paul, Designated Federal Officer (DFO) NACMH, HRSA, Office of Policy and Program Development, Bureau of Primary Health Care, HRSA, 5600 Fishers Lane, 16N38B, Rockville, Maryland 20857; 301–594–4300; or epaul@hrsa.gov.

SUPPLEMENTARY INFORMATION: NACMH provides advice and recommendations to the Secretary of HHS on policy, program development, and other matters of significance concerning the activities under Section 330(g) of the Public Health Service (PHS) Act (42 U.S.C. 254b). Pursuant to 42 U.S.C. 218, NACMH advises, consults with, and makes recommendations to the Secretary of HHS regarding the organization, operation, selection, and funding of migrant health centers and other entities funded under Section 330(g) of the PHS Act (42 U.S.C. 254b).

During the November 14 through 15, 2018, meeting, NACMH will discuss its general business activities. The Council will also hear presentations from federal officials and experts on issues facing agricultural workers, including the status of agricultural worker health at the local and national levels. Topics addressed at this meeting include:

- I. Patient Engagement Strategies;
- II. Recruitment and Retention of Health Care Providers;
- III. Human Trafficking in Agriculture; and
- IV. Health Literacy.

Agenda items are subject to change as priorities dictate. Refer to the NACMH website for any updated information concerning the meeting.

Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting. Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to NACMH should be sent to Esther Paul, DFO, using the contact information above at least 3 business days prior to the meeting.

Individuals who plan to attend and need special assistance or another reasonable accommodation should notify Esther Paul at the address and

phone number listed above at least 10 business days prior to the meeting.

Amy P. McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2018–20268 Filed 9–17–18; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Program Project Grant P01.

Date: October 17–18, 2018.

Time: 11:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Ana Olariu, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496–9223, Ana.olariu@nih.gov.

Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders A.

Date: October 22–23, 2018.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Avenue, Washington, DC 20037.

Contact Person: Natalia Strunnikova, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 402–0288, natalia.strunnikova@nih.gov.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; BRAIN eTeamBCP Integrated U01 Review.

Date: October 26, 2018.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Crystal City, 2399 Jefferson Davis Hwy., Arlington, VA 22202.

Contact Person: Ernest W. Lyons, Ph.D., Chief, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496–4056, lyonse@ninds.nih.gov.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; BRAIN Initiative—Postdoctoral Career Transition Award to Promote Diversity (K99/R00).

Date: October 26, 2018.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: The Alexandrian, 480 King Street, Alexandria, VA 22314.

Contact Person: Elizabeth A. Webber, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496–1917, webbere@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: September 12, 2018.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–20267 Filed 9–17–18; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NIDDK.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Diabetes and Digestive and Kidney Diseases, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.